One of Our Biggest Hopes For Alzheimer's Treatment Doesn't Seem to Work - ScienceAlert

A new study from Osaka Metropolitan University indicates that the Alzheimer's treatment lecanemab, which successfully lowers amyloid-beta protein levels in the brain, does not restore the brain's glymphatic system functionality in the short term. This system is essential for clearing waste, and its impairment is linked to Alzheimer's disease. The research, involving 13 patients, utilized magnetic resonance imaging to assess changes in brain function. Although lecanemab reduces plaque buildup, it does not seem to reverse existing neuronal damage or restore lost functions, suggesting that amyloid-beta clearance might not significantly alleviate the symptoms of Alzheimer's. The study author, Tatsushi Oura, emphasized the complexity of Alzheimer's, hinting that the amyloid plaques may result from the disease rather than cause it. The necessity for early detection of dementia symptoms is highlighted, as lecanemab shows more effectiveness at the disease's initial stages. Researchers aim to explore various factors affecting treatment outcomes, including age and disease stage, to optimize future therapies.